The Effects of Intra-articular and Peri-articular Platelet-rich Plasma (PRP) Injections ın Chronic Knee Osteoarthritis

NCT ID: NCT07339137

Last Updated: 2026-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate and compare the effectiveness of ultrasound-guided combined intra-articular and peri-articular platelet-rich plasma (PRP) injections with intra-articular PRP injections alone in patients with chronic knee osteoarthritis (OA). The study specifically examines the effects of these treatment approaches on pain, physical function, activities of daily living, and structural parameters, including medial collateral ligament (MCL) thickness and distal femoral cartilage thickness.

Osteoarthritis is a degenerative joint disease characterized by progressive cartilage erosion, osteophyte formation, and subchondral sclerosis, leading to pain, stiffness, and functional disability. It is the most common form of arthritis and a leading cause of disability worldwide, affecting approximately 300 million individuals. Although the knee is the most frequently involved joint, OA is now recognized as a whole-joint disease, involving not only cartilage degeneration but also pathological changes in subchondral bone, synovium, and surrounding extra-articular structures.

Platelet-rich plasma is an autologous concentration of platelets suspended in a small volume of plasma and contains a variety of bioactive growth factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). These factors play a crucial role in promoting cell proliferation, angiogenesis, and tissue repair. In knee OA, PRP has been shown to reduce matrix metalloproteinase (MMP) activity, particularly MMP-13, enhance endogenous hyaluronic acid production, and support chondrogenesis. Although intra-articular PRP injections are widely accepted as a safe and effective treatment and have demonstrated superiority over placebo and hyaluronic acid in long-term follow-up studies, most existing research has focused exclusively on intra-articular applications.

Knee OA is a multifactorial condition frequently associated with extra-articular pathologies, including ligament laxity, peri-articular edema, and soft tissue inflammation. Limiting treatment to the intra-articular space alone may therefore overlook these important contributors to pain and functional impairment. Emerging evidence suggests that a combined treatment approach targeting both intra-articular and peri-articular structures may provide superior outcomes in terms of pain reduction and functional improvement.

This prospective randomized controlled trial will include 42 patients aged 40-65 years with chronic knee OA classified as Kellgren-Lawrence grade 2 or 3. Participants will be randomly assigned to one of three groups: a control group receiving conservative treatment only (exercise therapy and lifestyle modifications), a group receiving conservative treatment plus ultrasound-guided intra-articular PRP injections, and a third group receiving conservative treatment plus combined ultrasound-guided intra-articular and peri-articular PRP injections targeting the MCL and pes anserinus regions.

Clinical outcomes will be assessed using validated instruments, including the Visual Analog Scale (VAS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Short Form-36 (SF-36) Quality of Life Scale. In addition, ultrasonographic measurements of MCL thickness and distal femoral cartilage thickness will be performed to evaluate structural changes. By investigating the additional value of peri-articular PRP injections, this study aims to contribute to the development of more comprehensive and effective injection protocols for the management of chronic knee osteoarthritis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Osteoarthritis (OA) is a dynamic condition characterized by a disruption in the balance between anabolic and catabolic processes of joint matrix molecules, favoring catabolism. Although OA is primarily recognized for cartilage degeneration, its pathogenesis involves a complex inflammatory and degenerative process affecting the entire joint unit, including subchondral bone, synovium, and surrounding soft tissues. Platelet-rich plasma (PRP) has emerged as an effective and safe treatment option for knee OA, particularly for patients who are unable to tolerate oral pharmacological therapies or wish to delay surgical intervention. PRP promotes tissue healing through the release of various growth factors from platelet alpha granules, which enhance cellular proliferation, stimulate angiogenesis, and reduce the activity of inflammatory mediators.

Current literature predominantly focuses on the efficacy of intra-articular PRP applications. However, knee OA is a multifactorial disease frequently accompanied by extra-articular pathologies, such as ligament laxity, edema, and peri-articular soft tissue inflammation. An exclusive focus on the intra-articular space may therefore overlook these extra-articular contributors to pain and functional impairment. This study is based on the hypothesis that a combined treatment approach targeting both the intra-articular environment and peri-articular structures-specifically the medial collateral ligament (MCL) and pes anserinus-will result in superior clinical outcomes compared to intra-articular treatment alone.

The use of ultrasound (USG) guidance in this study ensures accurate needle placement and enables objective assessment of structural changes. While intra-articular PRP has been shown to be more effective than hyaluronic acid or saline injections at 6- to 12-month follow-ups, evidence regarding the additional benefits of peri-articular PRP injections remains limited. To our knowledge, this study will be among the few randomized controlled trials comparing combined intra-articular and peri-articular PRP application with isolated intra-articular PRP treatment. Moreover, by evaluating changes in MCL thickness and distal femoral cartilage thickness using USG, this study aims to provide objective structural data to the existing literature.

In this prospective randomized controlled trial, 42 patients will be allocated into three groups. Group 1 (control group) will receive conservative treatment consisting of exercise therapy, lifestyle modifications, and patient education. Group 2 will receive conservative treatment in addition to three sessions of USG-guided intra-articular PRP injections administered at one-week intervals. Group 3 will receive conservative treatment plus three sessions of combined USG-guided intra-articular and peri-articular PRP injections, with peri-articular injections targeting the MCL origin and insertion sites as well as the pes anserinus tendon insertion.

All PRP applications will be performed using a standardized preparation kit and a photo-activation system to maximize growth factor release. Patients will be evaluated at baseline and followed up at 1 week and 3 months post-treatment using validated outcome measures, including the Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Short Form-36 (SF-36), along with ultrasonographic assessments to evaluate pain, function, and structural regeneration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Rich Plasma Injection Ultrasonography Gonarthrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This randomized, parallel-group study will compare the effects of conservative treatment alone, intra-articular platelet-rich plasma (PRP) injections in addition to conservative treatment, and combined intra-articular and peri-articular PRP injections in patients with chronic knee osteoarthritis (OA). Participants will be assigned to one of three intervention groups. Clinical and ultrasonographic outcomes will be assessed at baseline, 1 week after completion of treatment, and 3 months after completion of treatment.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Patients receiving guidance on conservative exercise therapy and lifestyle chang

Group Type ACTIVE_COMPARATOR

Conservative Therapy

Intervention Type BEHAVIORAL

Patients will receive guidance on conservative exercise therapy and lifestyle modifications. Exercise instruction forms will be provided, and patients will be shown how to perform the exercises correctly. Strengthening, stretching, and joint range of motion exercises targeting the quadriceps and hamstring muscle groups will be performed twice daily for 10 repetitions throughout the treatment period. Adherence will be monitored during follow-up visits.

Intra-articular PRP

Patients receiving intra-articular PRP therapy in addition to guidance on conservative exercise therapy and lifestyle chang

Group Type ACTIVE_COMPARATOR

Conservative Therapy

Intervention Type BEHAVIORAL

Patients will receive guidance on conservative exercise therapy and lifestyle modifications. Exercise instruction forms will be provided, and patients will be shown how to perform the exercises correctly. Strengthening, stretching, and joint range of motion exercises targeting the quadriceps and hamstring muscle groups will be performed twice daily for 10 repetitions throughout the treatment period. Adherence will be monitored during follow-up visits.

Intra-Articular PRP

Intervention Type PROCEDURE

Patients will receive intra-articular platelet-rich plasma (PRP) injections three times at one-week intervals. Following the PRP injections, patients will receive standard post-procedure recommendations, including resting the knee joint for 1-2 days, avoiding aggressive exercise, refraining from using nonsteroidal anti-inflammatory drugs (NSAIDs), and applying warm compresses as needed.

Combinated PRP (Intra and peri-articular PRP)

Patients receiving combined (periarticular and intraarticular PRP therapy) in addition to guidance on conservative exercise therapy and lifestyle chang

Group Type ACTIVE_COMPARATOR

Conservative Therapy

Intervention Type BEHAVIORAL

Patients will receive guidance on conservative exercise therapy and lifestyle modifications. Exercise instruction forms will be provided, and patients will be shown how to perform the exercises correctly. Strengthening, stretching, and joint range of motion exercises targeting the quadriceps and hamstring muscle groups will be performed twice daily for 10 repetitions throughout the treatment period. Adherence will be monitored during follow-up visits.

Intra-Articular PRP

Intervention Type PROCEDURE

Patients will receive intra-articular platelet-rich plasma (PRP) injections three times at one-week intervals. Following the PRP injections, patients will receive standard post-procedure recommendations, including resting the knee joint for 1-2 days, avoiding aggressive exercise, refraining from using nonsteroidal anti-inflammatory drugs (NSAIDs), and applying warm compresses as needed.

Peri-Articular PRP

Intervention Type PROCEDURE

Patients will receive peri-articular platelet-rich plasma (PRP) injections three times at one-week intervals. Following the PRP injections, patients will receive standard post-procedure recommendations, including resting the knee joint for 1-2 days, avoiding aggressive exercise, refraining from using nonsteroidal anti-inflammatory drugs (NSAIDs), and applying warm compresses as needed.

Peri-articular injections will be administered under ultrasound (USG) guidance to the origin and insertion sites of the medial collateral ligament (MCL), relevant joint areas, and the insertion points of the pes anserinus tendons.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conservative Therapy

Patients will receive guidance on conservative exercise therapy and lifestyle modifications. Exercise instruction forms will be provided, and patients will be shown how to perform the exercises correctly. Strengthening, stretching, and joint range of motion exercises targeting the quadriceps and hamstring muscle groups will be performed twice daily for 10 repetitions throughout the treatment period. Adherence will be monitored during follow-up visits.

Intervention Type BEHAVIORAL

Intra-Articular PRP

Patients will receive intra-articular platelet-rich plasma (PRP) injections three times at one-week intervals. Following the PRP injections, patients will receive standard post-procedure recommendations, including resting the knee joint for 1-2 days, avoiding aggressive exercise, refraining from using nonsteroidal anti-inflammatory drugs (NSAIDs), and applying warm compresses as needed.

Intervention Type PROCEDURE

Peri-Articular PRP

Patients will receive peri-articular platelet-rich plasma (PRP) injections three times at one-week intervals. Following the PRP injections, patients will receive standard post-procedure recommendations, including resting the knee joint for 1-2 days, avoiding aggressive exercise, refraining from using nonsteroidal anti-inflammatory drugs (NSAIDs), and applying warm compresses as needed.

Peri-articular injections will be administered under ultrasound (USG) guidance to the origin and insertion sites of the medial collateral ligament (MCL), relevant joint areas, and the insertion points of the pes anserinus tendons.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 40 and 65 years.
* Patients with significant medial knee pain who have not responded to conservative treatment for at least 3 months.
* Patients diagnosed with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria and with Kellgren-Lawrence grade 2 or 3 radiographic osteoarthritis.
* Intact cognitive function.
* Willingness to participate in the study and provide signed informed consent.
* Visual Analog Scale (VAS) score of 4 or higher.

Exclusion Criteria

* History of previous knee trauma or surgery.
* Physical therapy, intra-articular steroid, or hyaluronic acid injections in the knee within the last 3 months.
* Active oncological diseases.
* Local infection, sepsis, wounds, or scars in the injection area.
* Systemic infections, hepatitis, or immunosuppression.
* Bleeding diathesis or irregular International Normalized Ratio (INR) due to oral warfarin use.
* Inflammatory arthropathies.
* Uncontrolled hypertension, uncontrolled diabetes mellitus, decompensated heart failure, coronary artery disease, or asthma.
* Suspected or confirmed pregnancy.
* Use of corticosteroids or opioids.
* Anemia.
* Body mass index (BMI) greater than 35.
* Allergy to citrate.
* Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within the last week that may affect platelet function analyzer-100 (PFA-100) activity.
* Physical examination findings suggestive of patellar retinaculum, meniscus, or cruciate ligament injury.
* General health impairment or lack of cooperation.
* Refusal to participate in the study.
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara City Hospital Bilkent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

RIDVAN ÇELİK

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emre ADIGÜZEL, Prof. Dr.

Role: STUDY_DIRECTOR

Ankara Bilkent City Hospital Physical Therapy and Rehabilitation Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ankara Bilkent City Hospital, Physical Therapy and Rehabilitation Hospital

Ankara, Çankaya, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rıdvan E ÇELİK

Role: CONTACT

+905078414386

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rıdvan E ÇELİK

Role: primary

+905078414386

References

Explore related publications, articles, or registry entries linked to this study.

Pane RV, Setiyaningsih R, Widodo G, Al Hajiri AZZ, Salsabil JR. Femoral Cartilage Thickness in Knee Osteoarthritis Patients and Healthy Adults: An Ultrasound Measurement Comparison. ScientificWorldJournal. 2023 Feb 17;2023:3942802. doi: 10.1155/2023/3942802. eCollection 2023.

Reference Type BACKGROUND
PMID: 36845755 (View on PubMed)

Testa G, Giardina SMC, Culmone A, Vescio A, Turchetta M, Cannavo S, Pavone V. Intra-Articular Injections in Knee Osteoarthritis: A Review of Literature. J Funct Morphol Kinesiol. 2021 Feb 3;6(1):15. doi: 10.3390/jfmk6010015.

Reference Type BACKGROUND
PMID: 33546408 (View on PubMed)

Shen L, Yuan T, Chen S, Xie X, Zhang C. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. J Orthop Surg Res. 2017 Jan 23;12(1):16. doi: 10.1186/s13018-017-0521-3.

Reference Type BACKGROUND
PMID: 28115016 (View on PubMed)

Sit RWS, Wu RWK, Law SW, Zhang DD, Yip BHK, Ip AKK, Rabago D, Reeves KD, Wong SYS. Intra-articular and extra-articular platelet-rich plasma injections for knee osteoarthritis: A 26-week, single-arm, pilot feasibility study. Knee. 2019 Oct;26(5):1032-1040. doi: 10.1016/j.knee.2019.06.018. Epub 2019 Jul 30.

Reference Type BACKGROUND
PMID: 31375446 (View on PubMed)

Tao X, Aw AAL, Leeu JJ, Bin Abd Razak HR. Three Doses of Platelet-Rich Plasma Therapy Are More Effective Than One Dose of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis. Arthroscopy. 2023 Dec;39(12):2568-2576.e2. doi: 10.1016/j.arthro.2023.05.018. Epub 2023 May 24.

Reference Type BACKGROUND
PMID: 37236291 (View on PubMed)

Mascarenhas R, Saltzman BM, Fortier LA, Cole BJ. Role of platelet-rich plasma in articular cartilage injury and disease. J Knee Surg. 2015 Feb;28(1):3-10. doi: 10.1055/s-0034-1384672. Epub 2014 Jul 28.

Reference Type BACKGROUND
PMID: 25068847 (View on PubMed)

Aras B, Celik R, Tezen O, Adiguzel E. Associations of medial collateral ligament and cartilage thickness with clinical outcomes in medial knee osteoarthritis: a cross-sectional study. Clin Rheumatol. 2025 Nov 17. doi: 10.1007/s10067-025-07809-x. Online ahead of print.

Reference Type BACKGROUND
PMID: 41247668 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E2-25-9883

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.